ACIU AC IMMUNE SA

Competitive EU Grant Supports Collaboration to Accelerate Development of AC Immune's First-in-Class TDP-43 Diagnostic Agent

Competitive EU Grant Supports Collaboration to Accelerate Development of AC Immune's First-in-Class TDP-43 Diagnostic Agent
EN
09/10/2020

Underlying

ACIUAC IMMUNE SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AC IMMUNE SA

 PRESS RELEASE
Free
ACIU AC IMMUNE SA

AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from...

AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at AD/PDTM 2026 AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at AD/PDTM 2026 Initial data indicates significantly higher tracer uptake in patients with genetically defined FTDGood safety and tolerability and suitable PK profile for human brain imagingPotentially enables precision medicine across multiple neurodegenerative diseases Lausanne, Switzerland, March 19, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage ...

March 19, 2026 1 EN
 PRESS RELEASE
Free
ACIU AC IMMUNE SA

AC Immune Reports Full Year 2025 Financial Results and Provides a Corp...

AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update Phase 2 interim results suggest treatment with active immunotherapy ACI-7104 may slow the progression of Parkinson’s diseaseNLRP3 inhibitor ACI-19764 Phase 1 trial initiated with first participants dosed Approaching multiple value-inflection points, including interim results of the AD3 cohort in the Phase 2 ABATE trial of ACI-24 in Alzheimer’s disease in H1 2026, and full 24-month data from Part 1 of the Phase 2 VacSYn trial ...

March 13, 2026 1 EN
 PRESS RELEASE
Free
ACIU AC IMMUNE SA

AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease...

AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026 AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026 AC Immune to host symposium highlighting Precision Prevention approach to Parkinson's diseasePresentation at International Conference on Alzheimer’s and Parkinson’s Disease (AD/PD™ 2026) showcases potential of first-in-class TDP-43 PET-tracer ACI-19626 Lausanne, Switzerland, March 5, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision th...

March 5, 2026 1 EN
 PRESS RELEASE
Free
ACIU AC IMMUNE SA

AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor

AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor ACI-19764 is an orally available highly brain-penetrant small molecule NLRP3 inhibitorNLRP3 inhibitors are a major new class of compounds linked to a broad spectrum of inflammatory conditions including both metabolic and neurological diseasesACI-19764 is an important addition to AC Immune’s growing small molecule pipelinePhase 1 results in healthy volunteers are expected in H2 2026 Lausanne, Switzerland, February 24, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-s...

February 24, 2026 1 EN
Free Trial
ACIU AC IMMUNE SA

AC Immune Sa: 1 director

A director at AC Immune Sa sold 30,000 shares at 3.670USD and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

01/16/26 January 16, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch